SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced plans to implement a new infusion set
connector for Tandem insulin pump cartridges and infusion sets, the
t:lock™ Connector. Consistent with the philosophy followed for the
development of all of Tandem's products, the t:lock Connector was
designed based on direct customer feedback related to the process for
filling the infusion set with insulin. The new design reduces the time
required to fill the infusion set tubing by approximately 30 seconds and
reduces the amount of insulin used in the process by approximately four
and a half units.
"We strive to continue improving our products based on customer
feedback, and the length of our cartridge change process has
consistently been among the top requests," said Kim Blickenstaff,
President and CEO of Tandem Diabetes Care. "The new t:lock Connector
looks and feels like the current connector, but improves the overall
experience of changing the cartridge."
All the infusion sets currently offered by Tandem Diabetes Care will be
made available with the new t:lock Connector. The new infusion sets will
have the same insurance coverage as current sets.
Tandem expects to begin a gradual roll out of the new t:lock Connector
in the second half of 2017. The Company plans to offer both the current
connector as well as the t:lock Connector through the end of the year to
make the transition as smooth as possible for existing customers.
Current Tandem pump users will be contacted by Tandem or their current
supplies distributor with more information closer to the time of
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market; the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements; and the t:slim G4™ Insulin Pump, the first continuous
glucose monitoring-enabled pump with touchscreen simplicity. Tandem is
based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tslimG4, #tflex, #tconnect and $TNDM.
Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
t:slim, t:flex and Tandem Diabetes Care are registered trademarks, and
t:slim X2, t:slim G4 and t:lock are trademarks of Tandem Diabetes Care,
Inc. All other trademarks are the property of their respective owners.
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
include statements regarding the timing of the rollout of the t:lock
Connector and the Company's expectations that the t:lock Connector will
improve the overall experience of changing a cartridge. The Company's
actual results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties. For
instance, the infusion set compatible with the t:lock Connector may not
gain the regulatory approvals required for launch, the Company may be
unable to manufacture the t:lock cartridge and infusion set at volumes
necessary to support the needs of its existing and future customers, the
anticipated rollout period may take longer than anticipated, and the
Company may not ultimately be able to gain market acceptance for the
t:lock Connector. In addition, the Company's results may be impacted by
the other risks identified in the Company's most recent Annual Report on
Form 10-K, and other documents that the Company files with the
Securities and Exchange Commission. Investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this release. Tandem undertakes no obligation to update
or review any forward-looking statement in this press release because of
new information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170308005276/en/
For Tandem Diabetes Care, Inc.
Susan Morrison, 858-366-6900 x7005
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media